Literature DB >> 8580839

Solution structure of the catalytic domain of human stromelysin complexed with a hydrophobic inhibitor.

S R Van Doren1, A V Kurochkin, W Hu, Q Z Ye, L L Johnson, D J Hupe, E R Zuiderweg.   

Abstract

Stromelysin, a representative matrix metalloproteinase and target of drug development efforts, plays a prominent role in the pathological proteolysis associated with arthritis and secondarily in that of cancer metastasis and invasion. To provide a structural template to aid the development of therapeutic inhibitors, we have determined a medium-resolution structure of a 20-kDa complex of human stromelysin's catalytic domain with a hydrophobic peptidic inhibitor using multinuclear, multidimensional NMR spectroscopy. This domain of this zinc hydrolase contains a mixed beta-sheet comprising one antiparallel strand and four parallel strands, three helices, and a methionine-containing turn near the catalytic center. The ensemble of 20 structures was calculated using, on average, 8 interresidue NOE restraints per residue for the 166-residue protein fragment complexed with a 4-residue substrate analogue. The mean RMS deviation (RMSD) to the average structure for backbone heavy atoms is 0.91 A and for all heavy atoms is 1.42 A. The structure has good stereochemical properties, including its backbone torsion angles. The beta-sheet and alpha-helices of the catalytic domains of human stromelysin (NMR model) and human fibroblast collagenase (X-ray crystallographic model of Lovejoy B et al., 1994b, Biochemistry 33:8207-8217) superimpose well, having a pairwise RMSD for backbone heavy atoms of 2.28 A when three loop segments are disregarded. The hydroxamate-substituted inhibitor binds across the hydrophobic active site of stromelysin in an extended conformation. The first hydrophobic side chain is deeply buried in the principal S'1 subsite, the second hydrophobic side chain is located on the opposite side of the inhibitor backbone in the hydrophobic S'2 surface subsite, and a third hydrophobic side chain (P'3) lies at the surface.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580839      PMCID: PMC2143039          DOI: 10.1002/pro.5560041205

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  40 in total

Review 1.  The matrix-degrading metalloproteinases.

Authors:  L M Matrisian
Journal:  Bioessays       Date:  1992-07       Impact factor: 4.345

Review 2.  An evaluation of computational strategies for use in the determination of protein structure from distance constraints obtained by nuclear magnetic resonance.

Authors:  T F Havel
Journal:  Prog Biophys Mol Biol       Date:  1991       Impact factor: 3.667

Review 3.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

4.  Characterization of zinc-binding sites in human stromelysin-1: stoichiometry of the catalytic domain and identification of a cysteine ligand in the proenzyme.

Authors:  S P Salowe; A I Marcy; G C Cuca; C K Smith; I E Kopka; W K Hagmann; J D Hermes
Journal:  Biochemistry       Date:  1992-05-19       Impact factor: 3.162

5.  Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium.

Authors:  Y Okada; M Shinmei; O Tanaka; K Naka; A Kimura; I Nakanishi; M T Bayliss; K Iwata; H Nagase
Journal:  Lab Invest       Date:  1992-06       Impact factor: 5.662

6.  Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium.

Authors:  G S Firestein; M M Paine
Journal:  Am J Pathol       Date:  1992-06       Impact factor: 4.307

7.  Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids.

Authors:  D Grobelny; L Poncz; R E Galardy
Journal:  Biochemistry       Date:  1992-08-11       Impact factor: 3.162

8.  Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology.

Authors:  C Clavel; M Polette; M Doco; I Binninger; P Birembaut
Journal:  Bull Cancer       Date:  1992       Impact factor: 1.276

9.  Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone.

Authors:  Y Sasaguri; S Komiya; K Sugama; K Suzuki; A Inoue; M Morimatsu; H Nagase
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

10.  Structure of astacin and implications for activation of astacins and zinc-ligation of collagenases.

Authors:  W Bode; F X Gomis-Rüth; R Huber; R Zwilling; W Stöcker
Journal:  Nature       Date:  1992-07-09       Impact factor: 49.962

View more
  10 in total

1.  Dynamics of stromelysin/inhibitor interactions studied by 15N NMR relaxation measurements: comparison of ligand binding to the S1-S3 and S'1-S'3 subsites.

Authors:  P Yuan; V P Marshall; G L Petzold; R A Poorman; B J Stockman
Journal:  J Biomol NMR       Date:  1999-09       Impact factor: 2.835

Review 2.  Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.

Authors:  Klaus Maskos; Wolfram Bode
Journal:  Mol Biotechnol       Date:  2003-11       Impact factor: 2.695

3.  Conformational variability of matrix metalloproteinases: beyond a single 3D structure.

Authors:  Ivano Bertini; Vito Calderone; Marta Cosenza; Marco Fragai; Yong-Min Lee; Claudio Luchinat; Stefano Mangani; Beatrice Terni; Paola Turano
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

Review 4.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

5.  X-ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: implications for inhibitor selectivity.

Authors:  A G Pavlovsky; M G Williams; Q Z Ye; D F Ortwine; C F Purchase; A D White; V Dhanaraj; B D Roth; L L Johnson; D Hupe; C Humblet; T L Blundell
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

6.  Assignments and structure determination of the catalytic domain of human fibroblast collagenase using 3D double and triple resonance NMR spectroscopy.

Authors:  M A McCoy; M J Dellwo; D M Schneider; T M Banks; J Falvo; K J Vavra; A M Mathiowetz; M W Qoronfleh; R Ciccarelli; E R Cook; T A Pulvino; R C Wahl; H Wang
Journal:  J Biomol NMR       Date:  1997-01       Impact factor: 2.835

7.  Assignments, secondary structure and dynamics of the inhibitor-free catalytic fragment of human fibroblast collagenase.

Authors:  F J Moy; M R Pisano; P K Chanda; C Urbano; L M Killar; M L Sung; R Powers
Journal:  J Biomol NMR       Date:  1997-07       Impact factor: 2.835

8.  Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.

Authors:  Luis A Alcaraz; Lucia Banci; Ivano Bertini; Francesca Cantini; Antonio Donaire; Leonardo Gonnelli
Journal:  J Biol Inorg Chem       Date:  2007-08-21       Impact factor: 3.358

9.  Solution structures of stromelysin complexed to thiadiazole inhibitors.

Authors:  B J Stockman; D J Waldon; J A Gates; T A Scahill; D A Kloosterman; S A Mizsak; E J Jacobsen; K L Belonga; M A Mitchell; B Mao; J D Petke; L Goodman; E A Powers; S R Ledbetter; P S Kaytes; G Vogeli; V P Marshall; G L Petzold; R A Poorman
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

10.  A smallest 6 kda metalloprotease, mini-matrilysin, in living world: a revolutionary conserved zinc-dependent proteolytic domain- helix-loop-helix catalytic zinc binding domain (ZBD).

Authors:  Wei-Hsuan Yu; Po-Tsang Huang; Kuo-Long Lou; Shuan-Su C Yu; Chen Lin
Journal:  J Biomed Sci       Date:  2012-05-29       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.